Naxpar Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 5.00 Cr
as on 16-11-2024
- Company Age 20 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 122.92 Cr
as on 16-11-2024
- Satisfied Charges ₹ 17.29 Cr
as on 16-11-2024
- Revenue 2.48%
(FY 2023)
- Profit -3.74%
(FY 2023)
- Ebitda -1.14%
(FY 2023)
- Net Worth 16.21%
(FY 2023)
- Total Assets -3.09%
(FY 2023)
About Naxpar Pharma
The Corporate was formerly known as Parav Biopharm Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company currently has active open charges totaling ₹122.92 Cr. The company has closed loans amounting to ₹17.29 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mihir Shah, Baiju Shah, Prakash Shah, and Two other members serve as directors at the Company.
- CIN/LLPIN
U52310MH2004PTC144449
- Company No.
144449
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Feb 2004
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Naxpar Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mihir Shah  | Whole-Time Director | 10-Feb-2004 | Current |
| Baiju Shah | Whole-Time Director | 10-Feb-2004 | Current |
| Prakash Shah | Whole-Time Director | 10-Feb-2004 | Current |
| Harish Panpalia | Director | 11-Aug-2023 | Current |
| Yogesh Varia | Director | 28-May-2021 | Current |
Financial Performance of Naxpar Pharma.
Naxpar Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.48% increase. The company also saw a slight decrease in profitability, with a 3.74% decrease in profit. The company's net worth Soared by an impressive increase of 16.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Naxpar Pharma?
In 2023, Naxpar Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 13 Dec 2023 | ₹14.16 Cr | Open |
Hdfc Bank Limited Creation Date: 25 Jul 2023 | ₹0.98 M | Open |
Others Creation Date: 24 Dec 2021 | ₹4.00 Cr | Open |
How Many Employees Work at Naxpar Pharma?
Naxpar Pharma has a workforce of 448 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Naxpar Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Naxpar Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
